Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H29N3O2 |
| Molecular Weight | 343.4632 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCOC1=CC(C(=O)NCCN(CC)CC)=C2C=CC=CC2=N1
InChI
InChIKey=PUFQVTATUTYEAL-UHFFFAOYSA-N
InChI=1S/C20H29N3O2/c1-4-7-14-25-19-15-17(16-10-8-9-11-18(16)22-19)20(24)21-12-13-23(5-2)6-3/h8-11,15H,4-7,12-14H2,1-3H3,(H,21,24)
| Molecular Formula | C20H29N3O2 |
| Molecular Weight | 343.4632 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Dibucaine is used as a local anesthetic for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. Dibucaine is used to temporarily relieve pain and itching due to: hemorrhoids or other anorectal disorders, sunburn, minor burns, minor cuts; scrapes, insect bites, minor skin irritation. This drug acts via blocking of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions through sodium channel blocking. This reversibly stabilizes the membrane and inhibits depolarization, resulting in the failure of a propagated action potential and subsequent conduction blockade.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22279188
Curator's Comment: small amounts of drug likely cross the blood-brain barrier because dibucaine is neurotoxic at higher concentrations in patients
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1980 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9742684 |
|||
Target ID: CHEMBL5451 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9742684 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Nupercainal Approved Usetemporarily relieves pain and itching due to: - hemorrhoids or other anorectal disorders - sunburn - minor burns - minor cuts- scrapes - insect bites - minor skin irritation |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
23 ng/mL |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIBUCAINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
208 ng × h/mL |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIBUCAINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
11 h |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIBUCAINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Nitric oxide production by the vacuolar-type (H+)-ATPase inhibitors bafilomycin A1 and concanamycin A and its possible role in apoptosis in RAW 264.7 cells. | 2006-11 |
|
| Overexpression of RGPR-p117 enhances regucalcin gene promoter activity in cloned normal rat kidney proximal tubular epithelial cells: involvement of TTGGC motif. | 2006-10-01 |
|
| Involvement of nuclear factor I-A1 in the regulation of regucalcin gene promoter activity in cloned normal rat kidney proximal tubular epithelial cells. | 2006-10 |
|
| Verapamil, a Ca2+ channel inhibitor acts as a local anesthetic and induces the sigma E dependent extra-cytoplasmic stress response in E. coli. | 2006-10 |
|
| Inhibition of scratching behavior associated with allergic dermatitis in mice by tacrolimus, but not by dexamethasone. | 2006-09-28 |
|
| Effects of dibucaine on the endocytic/exocytic pathways in Trypanosoma cruzi. | 2006-09 |
|
| Regulatory effect of exogenous regucalcin on cell function in osteoblastic MC3T3-E1 cells: involvement of intracellular signaling factor. | 2006-08 |
|
| Supramolecular binding of protonated amines to a receptor microgel in aqueous medium. | 2006-06-21 |
|
| Divergence paresis without positional headache: an unusual presentation of cerebrospinal fluid hypovolemia after spinal anesthesia. | 2006-06 |
|
| [Butyrylcholinesterase deficiency: how to analyse the cholinesterase activity in small children?]. | 2006-06 |
|
| Effect of various formulation variables on the encapsulation and stability of dibucaine base in multilamellar vesicles. | 2006-02-08 |
|
| Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. | 2006-02 |
|
| False positives and false negatives with a cocaine-specific field test and modification of test protocol to reduce false decision. | 2005-12-20 |
|
| [Anogenital dermatoses--allergic and irritative causative factors. Analysis of IVDK data and review of the literature]. | 2005-12 |
|
| Overexpression of RGPR-p117 enhances regucalcin gene expression in cloned normal rat kidney proximal tubular epithelial cells. | 2005-12 |
|
| Pseudocholinesterase polymorphism in an Irish population. | 2005-11 |
|
| Overexpression of regucalcin suppresses cell proliferation in cloned rat hepatoma H4-II-E cells: involvement of intracellular signaling factors and cell cycle-related genes. | 2005-08-15 |
|
| Activation of calcium-independent phospholipase A (iPLA) in brain mitochondria and release of apoptogenic factors by BAX and truncated BID. | 2005-08 |
|
| Prescription pattern for treatment of hemorrhoids under the universal coverage policy of Thailand. | 2005-07 |
|
| Hormonal regulation on regucalcin mRNA expression in cloned normal rat kidney proximal tubular epithelial NRK52E cells. | 2005-06-01 |
|
| Cinchocaine hydrochloride determination by atomic absorption spectrometry and spectrophotometry. | 2005-05 |
|
| Wetting of surfactant solutions by alkanes. | 2005-03 |
|
| Genotyping the butyrylcholinesterase in patients with prolonged neuromuscular block after succinylcholine. | 2005-03 |
|
| Rapid accurate mass desorption electrospray ionisation tandem mass spectrometry of pharmaceutical samples. | 2005 |
|
| Cd2+ versus Ca2+-produced mitochondrial membrane permeabilization: a proposed direct participation of respiratory complexes I and III. | 2004-12-07 |
|
| Role of albumin in osteoblastic cells: enhancement of cell proliferation and suppression of alkaline phosphatase activity. | 2004-12 |
|
| Microfabricated fractal branching networks. | 2004-11-01 |
|
| Protective actions of various local anesthetics against the membrane dysfunction produced by in vitro ischemia in rat hippocampal CA1 neurons. | 2004-11 |
|
| Overexpression of regucalcin suppresses cell death and apoptosis in cloned rat hepatoma H4-II-E cells induced by lipopolysaccharide, PD 98059, dibucaine, or Bay K 8644. | 2004-10-15 |
|
| Preferential partitioning of uncharged local anesthetics into the surface-adsorbed film. | 2004-10-10 |
|
| [Allergy to formaldehyde]. | 2004-09 |
|
| [Glucose attenuating local anesthetic-induced hemolysis]. | 2004-09 |
|
| A new look at the hemolytic effect of local anesthetics, considering their real membrane/water partitioning at pH 7.4. | 2004-08-01 |
|
| Local anaesthetics--Nupercaine and Amethcaine. | 2004-08 |
|
| Randomized, double-blind trial comparing topical nitroglycerine with xylocaine and Proctosedyl in idiopathic chronic anal fissure. | 2004-07-15 |
|
| Evaluation of antipruritic effects of several agents on scratching behavior by NC/Nga mice. | 2004-07-14 |
|
| Apoptotic-like mitochondrial events associated to phosphatidylserine exposure in blood platelets induced by local anaesthetics. | 2004-07 |
|
| Effect of the glycosphingolipid, GM1 on localization of dibucaine in phospholipid vesicles: a fluorescence study. | 2004-07 |
|
| Some amphiphilic cations block the mitochondrial apoptosis-induced channel, MAC. | 2004-06-18 |
|
| Interaction of serotonin1A receptors from bovine hippocampus with tertiary amine local anesthetics. | 2004-06 |
|
| Probing the mechanism of drug/lipid membrane interactions using Biacore. | 2004-05-15 |
|
| Ethnic differences in the frequency of distribution of serum cholinesterase activity in the Iranian population. | 2004-05 |
|
| Quantitative evaluation of the effects of mitochondrial permeability transition pore modifiers on accumulation of calcium phosphate: comparison of rat liver and brain mitochondria. | 2004-04-01 |
|
| [Cauda equina syndrome following intrathecal dibucaine]. | 2004-04 |
|
| Possible mechanism of irreversible nerve injury caused by local anesthetics: detergent properties of local anesthetics and membrane disruption. | 2004-04 |
|
| Anesthesiology, the birth of pharmacogenetics and Werner Kalow. | 2004-03 |
|
| [What we can learn from a case of medical malpractice]. | 2004-02 |
|
| p-Bromophenacyl bromide prevents cumene hydroperoxide-induced mitochondrial permeability transition by inhibiting pyridine nucleotide oxidation. | 2004 |
|
| An improvement in segregation of human butyrylcholinesterase phenotypes having the fluoride-resistant variants. | 2003-12 |
|
| [Ionic strength influences hemolytic action of dibucaine hydrochloride]. | 2003-11 |
Sample Use Guides
If possible clean the affected area with mild soap and warm water and rinse thoroughly. Gently dry by patting or blotting with toilet tissue or a soft cloth before applying.
Adults and children 12 and over - apply externally to the affected area up to 3 to 4 times a day.
Children under 2 - 12 years of age - ask a doctor
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6181248
Exposure of spinal nerves to dibucaine reduces the quantity of 3H-proteins, which is transported to a ligature by 72% at 0.5 mM and by greater than 90% at a 1 mM concentration; since 1 mM tetracaine reduces it by 64%, dibucaine is approximately twice as potent as tetracaine at inhibiting transport.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 09:30:39 GMT 2025
by
admin
on
Wed Apr 02 09:30:39 GMT 2025
|
| Record UNII |
L6JW2TJG99
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 310.538
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
||
|
WHO-ATC |
D04AB02
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
||
|
WHO-VATC |
QC05AD04
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
||
|
NDF-RT |
N0000185508
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
||
|
WHO-ATC |
S01HA06
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
||
|
NCI_THESAURUS |
C245
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
||
|
WHO-VATC |
QN01BB06
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
||
|
WHO-ATC |
N01BB06
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
||
|
WHO-ATC |
S02DA04
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
||
|
CFR |
21 CFR 346.10
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
||
|
WHO-VATC |
QS02DA04
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
||
|
WHO-VATC |
QD04AB02
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
||
|
WHO-VATC |
QS01HA06
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
||
|
WHO-ATC |
C05AD04
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB06287MIG
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
PRIMARY | |||
|
N0000171131
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
PRIMARY | Allergens [Chemical/Ingredient] | ||
|
N0000175629
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
PRIMARY | Increased Histamine Release [PE] | ||
|
DB00527
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
PRIMARY | |||
|
DTXSID3045271
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
PRIMARY | |||
|
3025
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
PRIMARY | |||
|
3312
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
PRIMARY | |||
|
Cinchocaine
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
PRIMARY | |||
|
201-632-1
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
PRIMARY | |||
|
L6JW2TJG99
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
PRIMARY | |||
|
7159
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
PRIMARY | |||
|
859
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
PRIMARY | |||
|
3339
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
PRIMARY | RxNorm | ||
|
N0000184306
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
PRIMARY | Cell-mediated Immunity [PE] | ||
|
CHEMBL1086
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
PRIMARY | |||
|
m4306
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
PRIMARY | Merck Index | ||
|
108
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
PRIMARY | |||
|
C28984
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
PRIMARY | |||
|
L6JW2TJG99
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
PRIMARY | |||
|
D003992
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
PRIMARY | |||
|
159055
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
PRIMARY | |||
|
85-79-0
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
PRIMARY | |||
|
100000081060
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
PRIMARY | |||
|
247956
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
PRIMARY | |||
|
Dibucaine
Created by
admin on Wed Apr 02 09:30:39 GMT 2025 , Edited by admin on Wed Apr 02 09:30:39 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |